^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Adenocarcinoma
    Drug:pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The Clinical Effect of EGFR-TKI Combined with Chemotherapy on Patients with EGFR Multiple Mutation

    Excerpt:
    ......
    Trial ID:
    ChiCTR1800016672
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Sci Rep
    Title:

    PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy

    Published date:
    09/30/2020
    Excerpt:
    122 advanced lung adenocarcinoma patients who received pemetrexed maintenance therapy were retrospectively analyzed. Kaplan-Meier method with Log-rank test was used for survival analysis….The mPFS of ALK-positive patients was superior to negative patients (18.27 vs. 11.90 months; P = 0.039).
    DOI:
    10.1038/s41598-020-73013-3